Current securities fraud doctrine applying section 10(b) and Rule 10b-5 set a high bar for civil damages plaintiffs who must plead and prove both loss causation and transaction causation in order to prevail. Such a strict standard is not demanded by the law, given that the purpose of the Securities Act of 1933 and Securities Exchange Act of 1934 was to provide more protection for investors than had the common law of fraud. Nonetheless, the courts, especially the Supreme Court in Dura Pharmaceuticals v. Broudo, have chosen to impose this additional requirement. This Article examines the behavioral psychology literature, much of which is traceable to the work of Nobel Prize-winner Daniel Kahneman, in order to determine whether such a strict s...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...
The Supreme Court is about to hear Dura Pharmaceuticals Inc. v. Broudo, a case in which the Ninth Ci...
This article examines the element of scienter (fraudulent intent) in claims of federal securities fr...
Current securities fraud doctrine applying section 10(b) and Rule 10b-5 set a high bar for civil dam...
Plaintiffs in securities fraud class actions must prove that defendants’ misconduct caused the inves...
Abstract This article explores the economic principles and theories underlying loss causation in th...
The Supreme Court’s decision in Dura Pharmaceuticals dramatically changed federal securities fraud l...
As a critical matter, class action securities fraud plaintiffs employing the fraud-on-the-market the...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
On April 19, 2005, the Supreme Court announced its unanimous opinion in Dura Pharmaceuticals, Inc. v...
Since the Supreme Court’s landmark holding in Basic, Inc. v. Levinson, courts have incorporated the ...
An issuer makes a positive, material misstatement in violation of Rule 10b-5. What must an investor ...
The judicial view of a “reasonable investor” plays an important role in federal securities regulatio...
In 2005, the U.S. Supreme Court decided Dura Pharmaceuticals, Inc. v. Broudo. The Court held that a...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...
The Supreme Court is about to hear Dura Pharmaceuticals Inc. v. Broudo, a case in which the Ninth Ci...
This article examines the element of scienter (fraudulent intent) in claims of federal securities fr...
Current securities fraud doctrine applying section 10(b) and Rule 10b-5 set a high bar for civil dam...
Plaintiffs in securities fraud class actions must prove that defendants’ misconduct caused the inves...
Abstract This article explores the economic principles and theories underlying loss causation in th...
The Supreme Court’s decision in Dura Pharmaceuticals dramatically changed federal securities fraud l...
As a critical matter, class action securities fraud plaintiffs employing the fraud-on-the-market the...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
No coherent doctrinal statement exists for calculating open-market damages for securities fraud cl...
On April 19, 2005, the Supreme Court announced its unanimous opinion in Dura Pharmaceuticals, Inc. v...
Since the Supreme Court’s landmark holding in Basic, Inc. v. Levinson, courts have incorporated the ...
An issuer makes a positive, material misstatement in violation of Rule 10b-5. What must an investor ...
The judicial view of a “reasonable investor” plays an important role in federal securities regulatio...
In 2005, the U.S. Supreme Court decided Dura Pharmaceuticals, Inc. v. Broudo. The Court held that a...
Created pursuant to section 10 of the 1934 Securities Act, Rule 10b-5 is a cornerstone of the federa...
The Supreme Court is about to hear Dura Pharmaceuticals Inc. v. Broudo, a case in which the Ninth Ci...
This article examines the element of scienter (fraudulent intent) in claims of federal securities fr...